LETTER TO

THE EDITOR
Maternal serum total activin A in pregnancies affected with fetal Down's syndrome
Sir: Measurement of inhibin A seems to be a clinically useful addition to second trimester screening for fetal Down's syndrome. Inhibin A levels in maternal serum samples from affected pregnancies are on average twofold higher than those in unaffected pregnancies. 1-' Inhibin A is a heterodimeric protein product of the placenta that consists of an a and a~A subunit. Related proteins, including precursors of the a inhibin subunit (pro-aC) and activin A, a~A-~A homodimer, are also secreted during the second trimester.
In our previous study of 20 Down's syndrome and 100 unaffected maternal serum samples, levels of inhibin A related analytes, including total inhibin (inhibin dimer plus a inhibin precursor), pro-aC, and activin, were not markedly different between groups and did not appear useful in prenatal screening. ' The activin assay used in our previous study, however, measured free activin, detecting only the fraction of serum activin not bound to the binding protein, follistatin. A total activin A assay has recently been introduced (Serotec Ltd, Oxford, England), enabling us to measure the levels of free and follistatin bound activin A simultaneously. We have used that assay to determine the levels of total activin A in second trimester maternal serum samples from Down's syndrome and unaffected pregnancies.
Because we no longer had sufficient quantities of samples from our previous study, a new set of maternal serum samples was assembled, comprising 10 Down's syndrome cases each matched with five unaffected con-trois for gestational age (same completed week) and duration of freezer storage (+/one week). The new sample set was similar to the previous sample set in that median triple marker values for cases were in the expected range; medians for a fetoprotein, unconjugated oestriol, and human chorionic gonadotrophin were 0.70, 0.64, and 2.20 multiples of the unaffected median (MoM), respectively, in the new sample set and 0.61, 0.69, and 2.24 MoM, respectively, in the previous sample set. The assay showed complete recovery of added recombinant activin A (kindly provided by Dr Yuzuru Eto, Central Research Laboratories, Ajinomoto Co, Inc, Kawasaki, Japan) and parallelism using a pool of second trimester maternal serum. Total activin A levels were unaffected by duration of freezer storage but increased with gestational age (10% per week during weeks 15-18). Therefore, matched rank analysis of the case--eontrol sets was performed (table   1) .
The median level of total activin A in the Down's syndrome cases was 1.25 times that of the unaffected (1.00 MoM), similar to the increase in free activin (1.16 MoM) described previously.' This increase in total activin A levels was significant (P = 0.04). In summary, both total activin A and free activin are modestly raised in second trimester maternal serum samples from Down's syndrome pregnancies. Neither activin marker, however, appears to be as clinically useful as inhibin A in second trimester prenatal serum screening.
